Septerna, INC Form 4 insider transactions

Third Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 25,000 shares of common stock on August 11, 2026 for $44.00 per share.

Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,334 shares of common stock on August 3, 2026.

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares of common stock on July 15, 2026 for $33.99 per share.

Septerna Inc. SVP Daniel D. Long sold company stock valued at over $100,000 through a pre-arranged 10b5-1 plan, while also acquiring shares via stock options.

RA Capital Management, L.P. and affiliated entities have reported the acquisition of a stock option for 15,000 shares of Septerna, Inc. (SEPN) common stock.

Septerna Inc. Chief People Officer Samira Shaikhly sold 2,178 shares of common stock for $6.81 each, as part of a pre-arranged 10b5-1 trading plan.

Septerna, Inc. Director Abraham Bassan acquired 15,000 stock options with an exercise price of $37.34, vesting under specific service conditions.

Septerna Inc. director Shalini Sharp has been granted 15,000 stock options with an exercise price of $37.34, vesting under specific service conditions.

Septerna, Inc. director Bernard Coulie has acquired 15,000 stock options, with vesting tied to service and the company's next annual meeting.

Septerna, Inc. director Jeffrey K. Tong acquired 15,000 stock options with an exercise price of $37.34, vesting in full by June 26, 2027, or the next annual meeting.

Septerna, Inc. reports a Form 4 filing detailing stock option grants to Director Keith Michael Gottesdiener.

Septerna, Inc. director Alan Ezekowitz was granted 15,000 stock options with an exercise price of $37.34, vesting in full by June 26, 2027 or the next annual meeting.

Septerna, Inc. Director Jake Simson acquired stock options, with the underlying shares held for the benefit of RA Capital Management funds.

Septerna, Inc. SVP of Drug Discovery, Daniel D. Long, engaged in a series of stock transactions, acquiring shares through an employee stock purchase plan and options, while also selling a portion of his holdings.

Chief People Officer Samira Shaikhly exercised options to acquire and subsequently sold 6,250 shares of Septerna, Inc. common stock.

Chief People Officer Samira Shaikhly exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Chief People Officer Samira Shaikhly exercised options for 11,798 shares of Septerna, Inc. and subsequently sold them under a Rule 10b5-1 plan.

Septerna President and COO Elizabeth Bhatt exercised stock options and sold shares under a pre-arranged 10b5-1 plan.

Septerna's Chief People Officer, Samira Shaikhly, exercised stock options and simultaneously sold an equal number of shares totaling over $1.98 million under a pre-arranged 10b5-1 plan.

Septerna, Inc.'s SVP of Drug Discovery, Daniel D. Long, was granted 80,000 stock options with an exercise price of $25.41, vesting over 48 months.

Septerna's SVP of Biological Sciences, Uwe Klein, was granted 80,000 stock options with a vesting schedule tied to continuous service.

Septerna's Chief People Officer, Samira Shaikhly, was granted 80,000 stock options with an exercise price of $25.41, vesting over approximately four years.

Septerna Inc.'s Chief Financial Officer, Gil M. Labrucherie, was granted 125,000 stock options with an exercise price of $25.41.

Septerna's Chief Medical Officer, Jae B. Kim, was granted 125,000 stock options with an exercise price of $25.41, vesting over approximately four years.

Septerna, Inc.'s President and COO, Elizabeth Bhatt, was granted 155,000 stock options with an exercise price of $25.41, vesting over 48 months.

Septerna, Inc. CEO Jeffrey Finer was granted 400,000 stock options with an exercise price of $25.41, vesting over approximately four years.

Septerna Inc.'s Chief Legal Officer, Mark Andrew Wilson, was granted 165,000 stock options with an exercise price of $25.41, vesting over four years.

Septerna Inc.'s SVP of Drug Discovery, Daniel D. Long, reported the sale of 3,501 shares of common stock at a weighted average price of $18.0586, executed under a Rule 10b5-1 plan.